Meet the Mesothelioma Experts: Evan Alley, MD Discusses New PD-L1 Clinical Trial

Dr. Evan Alley of UPenn

Learn more about the PD-LI clinical trial for pleural mesothelioma at the Meet the Mesothelioma Experts session with Dr. Evan Alley.

On May 14, 2014, at 8 PM Eastern time, the Mesothelioma Applied Research Foundation will be holding a new installment of its “Meet the Mesothelioma Experts” series featuring Dr. Evan Alley of the University of Pennsylvania, who will discuss his new clinical trial available to pleural mesothelioma patients. The clinical trial will look into an agent that would inhibit the PD-L1 protein.

This installment of the “Meet the Mesothelioma Experts” is made possible by a generous educational grant by The Edgar Lomax Company.

This “Meet the Mesothelioma Experts” session is made possible by a generous educational grant by The Edgar Lomax Company.

PD-L1 is a protein believed to play a role in suppressing the immune system. Generally, it is associated with pregnancy and autoimmune diseases. In cancer, a high tumor expression of PD-L1 is linked with more aggressive disease and a poorer prognosis. Research into PD-L1 inhibitors has already shown much promise in melanoma, renal cell carcinoma and lung cancer, evidencing both tumor shrinkage and durable response, and prompting a number of mesothelioma centers to open trials testing similar agents.

Dr. Alley will discuss trial details in an interview with Mary Hesdorffer, Meso Foundation’s executive director and expert mesothelioma nurse practitioner. The interview can be listened to “live” by calling into a conference-call number. All listeners must RSVP ahead of time by visiting: www.curemeso.org/experts.

Dr. Alley is part of the Penn Mesothelioma and Pleural Program team and the interim chief of the Division of Hematology and Medical Oncology at Penn Presbyterian Medical Center.

Dr. Alley of the University of Pennsylvania, who will discuss his new clinical trial available to pleural mesothelioma patients. The clinical trial will look into an agent that would inhibit the PD-L1 protein.
Starts: 05/14/2014 08:00 pm

4 Comments on "Meet the Mesothelioma Experts: Evan Alley, MD Discusses New PD-L1 Clinical Trial"

  1. This blog webpage indicates the session starts at 8PM, at the top. At the bottom of the page it says 8AM is the start time. The original email says 8PM. I’m guessing 8PM is correct.

  2. Michael Viggiano | May 14, 2014 at 8:51 pm | Reply

    My name is Michael Viggiano and I have plural meso. I was treated with cosy platinum and Altima I last year. I also have bone infection that was cause by radiation treatment for Hodgkin disease in1965. Would I be candidate for your trail. Please advise .Michael Viggiano

  3. Joan Viggiano | May 14, 2014 at 8:56 pm | Reply

    My husband Michael Viggiano has plural meso, he was treated with cyst planet and Altima .he now has a chronic bone infection due to radiation therapy which was given to him in 1965 for Hopkins lymphatic and then had a reoccur acne in 1975, and back then they did cobalt treatments that now cause the bone infection. They will not give him and more chemo because of that. Can he be a canidiate for clinical trail drug.

    Thank you
    Joan Viggiano

Leave a comment

Your email address will not be published.


*